SCM
TNYA icon

Stonepine Capital Management’s Tenaya Therapeutics TNYA Stock Holding History

Stonepine Capital Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-352,001
Closed -$250K – 99
2025
Q4 		$250K Buy
+352,001
New +$479K 0.18% 60

Other funds holding TNYA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's TNYA Position: Q1 2026 in Review

Stonepine Capital Management sold out of Tenaya Therapeutics (TNYA) in Q1 2026, closing a stake of 352,001 shares — an estimated $250K sold.

Stonepine Capital Management first reported a position in TNYA in Q4 2025 and held it in 1 quarter. The position peaked at $250K in Q4 2025. 103 funds tracked by Wall St. Rank hold TNYA as of Q1 2026.

  • Stonepine Capital Management reported no remaining Tenaya Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Stonepine Capital Management sold 352,001 Tenaya Therapeutics shares in Q1 2026, an estimated $250K.
  • Stonepine Capital Management first reported a position in Tenaya Therapeutics in Q4 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Tenaya Therapeutics position peaked at $250K in Q4 2025.
  • 103 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.